Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
NEW YORK, Aug. 15, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, announced today that Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development and Regulatory Affairs of NeoStem, has been invited to present at an industry conference next week on the topic of AMR-001, the Company's lead product candidate, in a talk titled "CD34 Stem Cells: Biology's Blueprint for Optimized Interventional Cardiology".
Help employers find you! Check out all the jobs and post your resume.
NEW YORK, Aug. 15, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, announced today that Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development and Regulatory Affairs of NeoStem, has been invited to present at an industry conference next week on the topic of AMR-001, the Company's lead product candidate, in a talk titled "CD34 Stem Cells: Biology's Blueprint for Optimized Interventional Cardiology".
Help employers find you! Check out all the jobs and post your resume.
